Tags

Type your tag names separated by a space and hit enter

What's new in bullous pemphigoid.
J Dermatol. 2010 Mar; 37(3):194-204.JD

Abstract

Bullous pemphigoid (BP) is the most common autoimmune blistering disease. BP patients have autoantibodies against type XVII collagen (COL17, also called BP180 or BPAG2), a type II transmembrane protein that spans the lamina lucida and projects into the lamina densa of the epidermal basement membrane. The non-collagenous 16A domain of COL17 is considered to contain pathogenic epitopes of BP. The transfer of immunoglobulin (Ig)G from BP patients fails to cause blisters on mouse skin probably due to differences between humans and mice in the amino acid sequence of NC16A pathogenic epitope of COL17. Passive transfer of rabbit IgG antibodies against the murine homolog of human COL17 NC16A triggers immune reactions to COL17 in mice, including complement activation, mast cell degranulation and neutrophilic infiltration, resulting in dermal-epidermal separation. Recent studies using COL17-humanized mice that express human COL17 but lack murine COL17 were the first to demonstrate the pathogenicity of anti-COL17 human BP IgG autoantibodies in vivo. These new findings provide a greater understanding of BP pathomechanisms and facilitate the development of novel specific and efficient therapeutic strategies for BP.

Authors+Show Affiliations

Department of Dermatology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan. h-ujiie@med.hokudai.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20507382

Citation

Ujiie, Hideyuki, et al. "What's New in Bullous Pemphigoid." The Journal of Dermatology, vol. 37, no. 3, 2010, pp. 194-204.
Ujiie H, Shibaki A, Nishie W, et al. What's new in bullous pemphigoid. J Dermatol. 2010;37(3):194-204.
Ujiie, H., Shibaki, A., Nishie, W., & Shimizu, H. (2010). What's new in bullous pemphigoid. The Journal of Dermatology, 37(3), 194-204. https://doi.org/10.1111/j.1346-8138.2009.00792.x
Ujiie H, et al. What's New in Bullous Pemphigoid. J Dermatol. 2010;37(3):194-204. PubMed PMID: 20507382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - What's new in bullous pemphigoid. AU - Ujiie,Hideyuki, AU - Shibaki,Akihiko, AU - Nishie,Wataru, AU - Shimizu,Hiroshi, PY - 2010/5/29/entrez PY - 2010/5/29/pubmed PY - 2010/9/2/medline SP - 194 EP - 204 JF - The Journal of dermatology JO - J Dermatol VL - 37 IS - 3 N2 - Bullous pemphigoid (BP) is the most common autoimmune blistering disease. BP patients have autoantibodies against type XVII collagen (COL17, also called BP180 or BPAG2), a type II transmembrane protein that spans the lamina lucida and projects into the lamina densa of the epidermal basement membrane. The non-collagenous 16A domain of COL17 is considered to contain pathogenic epitopes of BP. The transfer of immunoglobulin (Ig)G from BP patients fails to cause blisters on mouse skin probably due to differences between humans and mice in the amino acid sequence of NC16A pathogenic epitope of COL17. Passive transfer of rabbit IgG antibodies against the murine homolog of human COL17 NC16A triggers immune reactions to COL17 in mice, including complement activation, mast cell degranulation and neutrophilic infiltration, resulting in dermal-epidermal separation. Recent studies using COL17-humanized mice that express human COL17 but lack murine COL17 were the first to demonstrate the pathogenicity of anti-COL17 human BP IgG autoantibodies in vivo. These new findings provide a greater understanding of BP pathomechanisms and facilitate the development of novel specific and efficient therapeutic strategies for BP. SN - 1346-8138 UR - https://www.unboundmedicine.com/medline/citation/20507382/What's_new_in_bullous_pemphigoid_ DB - PRIME DP - Unbound Medicine ER -